Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.63 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thebacon SCHEMBL21304123 | 1.00 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| Thebacon SCHEMBL1649199 | 1.00 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| Thebacon SCHEMBL29632752 | 1.00 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| Thebacon SCHEMBL6240045 | 0.99 | OPRD1 (0.62) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL16922127 | 0.95 | OPRD1 (0.59) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18457704 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL12944986 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL10222572 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18457702 | 0.90 | OPRM1 (0.51) | OPRD1OPRM1OPRK1MRGPRX2PDE4D | |
| SCHEMBL12006856 | 0.90 | OPRM1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2209 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240165022-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-05-23 | — | — | US | claimed |
| US-11904049-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-02-20 | — | — | US | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-1121109-A2 | OPIOID ANALGESIC | Euroceltique S.A. (LU) | 2001-08-08 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000021520-A2 | OPIOID ANALGESIC | EUROCELTIQUE S.A. (LU) | 2000-04-20 | — | — | WO | claimed |
| EP-0984974-A1 | GLYCOCONJUGATES OF OPIATED SUBSTANCES | ROLABO S.L. (ES) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054196-A1 | GLYCOCONJUGATES OF OPIATED SUBSTANCES | ROLABO SL (ES) | 1998-12-03 | — | — | WO | claimed |
| CN-1196955-A | Thebaica giving-up vaccinum for man | KUNMING BIOLOG TECH ENGINEERIN (CN) | 1998-10-28 | — | — | CN | claimed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |